(Q28300843)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21155988%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

0 references

1 reference

title

The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21155988%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21155988%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Mariacarlotta Palazzo

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21155988%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Lucio Oldani

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21155988%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

4

A Carlo Altamura

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21155988%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

language of work or name

English

0 references

publication date

14 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21155988%20AND%20SRC:MED&resulttype=core&format=json

CNS Neuroscience & Therapeutics

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21155988%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21155988%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21155988%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

723-732

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21155988%20AND%20SRC:MED&resulttype=core&format=json

Norepinephrine in depressive reactions. A review

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

The catecholamine hypothesis of affective disorders: a review of supporting evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

An update on the role of glutamate in the pathophysiology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Evidence of cortical inhibitory deficits in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Genetics of HPA-axis, depression and suicidality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

A psychoneuroimmunological review on cytokines involved in antidepressant treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

The expression of VGF is reduced in leukocytes of depressed patients and it is restored by effective antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Serum and plasma BDNF levels in major depression: a replication study and meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Rethinking depression and the actions of antidepressants: uncovering the links between the neural and behavioral elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Psychopharmacology and the etiology of psychopathologic states: are we looking in the right way?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

5-Hydroxytryptamine pathways in anxiety and its treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Paraventricular hypothalamic nucleus: axonal projections to the brainstem

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Stimulation of alpha(1)-adrenoceptors reduces glutamatergic synaptic input from primary afferents through GABA(A) receptors and T-type Ca(2+) channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Serotonergic and noradrenergic modulation of emotion processing by single dose antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Serotonergic regulation of noradrenergic coerulean neurons: electrophysiological evidence for the involvement of 5-HT2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Interaction of brain noradrenergic system and the hypothalamic-pituitary-adrenal (HPA) axis in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Noradrenaline in mood and anxiety disorders: basic and clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

The metabolic fate of amitriptyline, nortriptyline and amitriptylinoxide in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Emerging treatments for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Treatment of poststroke generalized anxiety disorder comorbid with poststroke depression: merged analysis of nortriptyline trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

[Poisoning with antidepressants].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

MAOIs in the contemporary treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Social anxiety disorder : current treatment recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

The Promises and Pitfalls of Reboxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Clinical pharmacokinetics of atomoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Venlafaxine-induced psychotic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Venlafaxine in the treatment of anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Venlafaxine extended-release: a review of its use in the management of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Safety and adverse event profile of duloxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Atypical depression: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Effects of acute and sustained administration of the catecholamine reuptake inhibitor nomifensine on the firing activity of monoaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Hyperforin inhibits vesicular uptake of monoamines by dissipating pH gradient across synaptic vesicle membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Differential relationships among dopamine transporter affinities and stimulant potencies of various uptake inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Bupropion and desipramine increase dopamine transporter mRNA expression in the ventral tegmental area/substantia nigra of rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Use of bupropion in combination with serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Incidence and onset of delayed seizures after overdoses of extended-release bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Analytical method development and validation of mianserin hydrochloride and its metabolite in human plasma by LC-MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

21 January 2018

Mianserin metabolites

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Efficacy and side effects of mianserin, a tetracyclic antidepressant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Mirtazapine: a review of its use in major depression and other psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Triple reuptake inhibitors: the next generation of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Quetiapine XR: current status for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

The role of noradrenaline and selective noradrenaline reuptake inhibition in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00217.X

Physiology to functionality: the brain and neurotransmitter activity

21 January 2018

1 reference

12 December 2020

New approaches to the treatment of refractory depression.

1 reference

12 December 2020

Norepinephrine involvement in antidepressant action

1 reference

12 December 2020

Novel treatments for attention-deficit/hyperactivity disorder in children.

1 reference

12 December 2020

Reboxetine, a selective noradrenaline reuptake inhibitor for the treatment of depression.

1 reference

12 December 2020

The promises and pitfalls of reboxetine

1 reference

12 December 2020

Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials

1 reference

12 December 2020

Psychopharmacology for the clinician. Treating depression with selective norepinephrine reuptake inhibitors.

1 reference

12 December 2020

An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies

1 reference

12 December 2020

Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials.

1 reference

12 December 2020

Escitalopram in the treatment of major depressive disorder: a meta-analysis

1 reference

12 December 2020

Lower side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan

1 reference

12 December 2020

Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials.

1 reference

12 December 2020

First-line pharmacotherapies for depression - what is the best choice?

1 reference

12 December 2020

Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study.

1 reference

12 December 2020

Noradrenergic function in generalized anxiety disorder: impact of treatment with venlafaxine on the physiological and psychological responses to clonidine challenge

1 reference

12 December 2020

Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression

1 reference

12 December 2020

The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants

1 reference

12 December 2020

Trazodone in late life depressive states: a double-blind multicenter study versus amitriptyline and mianserin

1 reference

12 December 2020

Comparative effect of tropolone and diosmin on venous COMT and sympathetic activity in rat

1 reference

12 December 2020

Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior

1 reference

12 December 2020

Bupropion: a review of its mechanism of antidepressant activity.

1 reference

12 December 2020

Pharmacology of antidepressants--characteristics of the ideal drug

1 reference

12 December 2020

Mianserin: pharmacology and clinical aspects of an effective antidepressive agents

1 reference

12 December 2020

Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis

1 reference

12 December 2020

Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action

1 reference

12 December 2020

Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine

1 reference

12 December 2020

10.1111/J.1755-5949.2010.00217.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21155988%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21155988%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

PubMed publication ID

21155988

1 reference